Liraglutide
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Novo Nordisk · Phase 2 · Completed · Enrollment 834
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| MEDI0382 low dose + Metformin | T2D only | n/r | n/r | n/r | n/r |
| MEDI0382 mid dose + Metformin | T2D only | n/r | n/r | n/r | n/r |
| MEDI0382 high dose + Metformin | T2D only | n/r | n/r | n/r | n/r |
| Placebo + Metformin | T2D only | n/r | 14 | n/r | n/r |
| Liraglutide + Metformin | T2D only | n/r | n/r | n/r | n/r |
| MEDI0382 100 mcg | T2D only | 100 mcg | 14 | n/r | n/r |
| MEDI0382 200 mcg | T2D only | 200 mcg | 14 | n/r | n/r |
| MEDI0382 300 mcg | T2D only | 300 mcg | 14 | n/r | n/r |